← 홈

CGT · 림프종

305개 · ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 305개
CGTAHOTFDACuratedFDABiologicNovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA승인#바이오정보모아추천+5
효능 ORR 82.3%임상시험 48상태 APPROVED
CGTBHotBiologicGlaxoSmithKlinePhase 1

19 (T2, 19, 19(T2)28z1xx TRAC T cell)

B-Cell Lymphoma; Large B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase1#인기#세포유전치료+5
효능 ORR 100%임상시험 234상태 RECRUITING
CGTABiologicstaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 77.3%임상시험 96상태 RECRUITING
CGTBBiologicstaleBioceltech Therapeutics, Ltd.Phase 1

CD19 CAR T cells (CD19 CAR T cells)

B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#인기#세포유전치료+5
효능 ORR 88%임상시험 73상태 RECRUITING
CGTBiologicstaleJuventas Cell Therapy Ltd.Phase 2

CD19 CAR-T (CD19 CAR-T)

B-cell Malignancy; B-cell Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 88%임상시험 66상태 ACTIVE
CGTBiologicstaleAmgenPhase 3

Asparaginase Erwinia chrysanthemi (Asparaginase Erwinia chrysanthemi, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, recombinant)

Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma · Acute Lymphoblastic Leukemia

#AcuteLymphoblasticLeukemia#CGT#Phase3#인기#세포유전치료+5
효능 ORR 18%임상시험 64상태 RECRUITING
CGTBiologicstaleHoffmann-La RochePhase 1

Interferon-Alfa-2b (Interferon-Alfa-2b)

Solid Cancers · Adult T-cell Leukemia-Lymphoma

#AdultT-cellLeukemia-Lymphoma#CGT#Phase1#인기#세포유전치료+5
효능 ORR 24%임상시험 63상태 ACTIVE
CGTBiologicstaleTakedaPhase 1

19 (T2, 19, 19(T2)28z1xx CAR T cells)

Diffuse Large B Cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Phase1#인기#세포유전치료+5
효능 ORR 17%임상시험 62상태 RECRUITING
CGTBiologicstaleShenzhen BinDeBio Ltd.mayPhase 2

CAR-T cell immunotherapy (CAR-T cell immunotherapy)

B-cell Acute Lymphoblastic Leukemia; Lymphoma · GD2

#GD2#CGT#Phase2#인기#세포유전치료+5
효능 ORR 80.3%임상시험 62상태 ACTIVE
CGTBiologicstaleFondazione Policlinico Universi…sPreclinical

Chimeric Antigen Receptor (Chimeric Antigen Receptor)

Lymphoma · Lymphoma

#Lymphoma#CGT#Preclinical#인기#세포유전치료+4
효능 ORR 67%임상시험 62상태 RECRUITING
CGTBiologicstaleMerck Sharp & Dohme LLCPhase 2

Stem cell infusion (Stem cell infusion)

Leukemia; Lymphoma · Leukemia

#Leukemia#CGT#Phase2#인기#세포유전치료+5
효능 ORR 90%임상시험 62상태 ACTIVE
CGTBiologicstaleYake Biotechnology Ltd.Phase 1

chimeric antigen receptor T cell treatment (chimeric antigen receptor T cell treatment)

T Cell Lymphoma; T-cell Leukemia · FRα

#FR#CGT#Phase1#인기#세포유전치료+5
효능 ORR 80.3%임상시험 62상태 ACTIVE
CGTBiologicstaleHebei Senlang Biotechnology Inc…Phase 2

Autologous CAR-T cells (Autologous CAR-T cells)

Leukemia; Lymphoma · FRα

#FR#CGT#Phase2#인기#세포유전치료+5
효능 ORR 80.3%임상시험 61상태 ACTIVE
CGTBiologicSanofiPhase 2

gemcitabin (gemcitabin)

Extranodal NK/T-cell Lymphoma, Nasal Type · Extranodal NK/T-cell Lymphoma, Nasal Typ

#ExtranodalNKT-cellLymphomaNasalT#CGT#Phase2#인기#세포유전치료+5
효능 ORR 32%임상시험 61상태 ACTIVE
CGTBiologicstaleSinobioway Cell Therapy Co., Lt…Preclinical

CD19-targeted CAR-T cells (CD19-targeted CAR-T cells)

Lymphoma · CD19

#CD19#CGT#Preclinical#인기#세포유전치료+5
효능 ORR 94%임상시험 60상태 ACTIVE
CGTBiologicstaleBellicum PharmaceuticalssPhase 2

Chimeric antigen receptor (CAR, Chimeric antigen receptor, Chimeric antigen receptor (CAR) T-cell therapy)

Diffuse Large B Cell Lymphoma · Diffuse Large B Cell Lymphoma

#DiffuseLargeBCellLymphoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 80.3%임상시험 60상태 RECRUITING
CGTBiologicstaleAbbottvedotinPhase 2

Zidovudine (Zidovudine)

Lymphoproliferative Disorder; HHV-8 · Adult T-cell Leukemia-Lymphoma

#AdultT-cellLeukemia-Lymphoma#CGT#Phase2#인기#세포유전치료+5
임상시험 60상태 RECRUITING
CGTBiologicstaleAbClonvedotin-containing regimens…Phase 2

Anti-CD19 Chimeric Antigen Receptor T cell (AT101, AT101(Anti-CD19 Chimeric Antigen Receptor T cell))

B-cell Non Hodgkin Lymphoma · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5
효능 ORR 38%임상시험 59상태 RECRUITING
CGTBiologicstalePaolo Caimi, MDPhase 1

Allogeneic NK cells (Allogeneic NK cells)

Non Hodgkin Lymphoma; B-cell Non Hodgkin Lymphoma · Non Hodgkin Lymphoma

#NonHodgkinLymphoma#CGT#Phase1#인기#세포유전치료+4
효능 ORR 5%임상시험 58상태 RECRUITING
CGTBiologicstaleNovartis PharmaceuticalsPhase 2

Bridging Therapy (Bridging Therapy)

Non-Hodgkin Lymphoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#CGT#Phase2#인기#세포유전치료+4
효능 ORR 32.1%임상시험 58상태 DISCONTINUED

1 / 16 페이지

← 이전다음 →